Last reviewed 2026-04-19 · How we verify

Hespecta

Leiden University · Phase 1 active Biologic

Hespecta is a Biologic drug developed by Leiden University. It is currently in Phase 1 development. Also known as: HPV 16 E6 synthetic peptides (E6 71-95 and E6 127-158).

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Hespecta
Also known as	HPV 16 E6 synthetic peptides (E6 71-95 and E6 127-158)
Sponsor	Leiden University
Modality	Biologic
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Hespecta Vaccination in HPV+ Tumors or Malignant Lesions (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Hespecta CI brief — competitive landscape report
Hespecta updates RSS · CI watch RSS
Leiden University portfolio CI

Frequently asked questions about Hespecta

What is Hespecta?

Hespecta is a Biologic drug developed by Leiden University.

Who makes Hespecta?

Hespecta is developed by Leiden University (see full Leiden University pipeline at /company/leiden-university).

Is Hespecta also known as anything else?

Hespecta is also known as HPV 16 E6 synthetic peptides (E6 71-95 and E6 127-158).

What development phase is Hespecta in?

Hespecta is in Phase 1.

Manufacturer: Leiden University — full pipeline
Therapeutic area: All drugs in Other
Also known as: HPV 16 E6 synthetic peptides (E6 71-95 and E6 127-158)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing